Wim D.
- Country
- Belgium
- Department
- Oncology
Research Overview
- Phase III Randomized Double‑Blind Placebo‑Controlled Trial of Low‑Dose Acetylsalicylic Acid for Recurrence and Overall Survival in Resected Stage II–III Colon Cancer
- Efficacy and Safety of REGN7508 for Primary Prophylaxis of Cancer-Associated Thrombosis in Patients with Solid Tumors Undergoing Cancer Treatment
- Phase III Randomized Open‑Label Study of Atezolizumab + Lenvatinib or Sorafenib vs Lenvatinib/Sorafenib Alone in Previously Treated Unresectable HCC
Data & Insights
Has run more than one trial at 475 of 834 partner sites.
Specializations
Breast Cancer Research
Specializes in advanced therapeutic approaches for hormone receptor-positive (HR+) and HER2-negative breast cancer, with particular focus on early-stage and metastatic breast cancer treatment. Investigates novel endocrine therapies and targeted treatments including elacestrant and capivasertib combinations.
- Hormone Receptor-Positive Disease Management
- Triple-Negative Breast Cancer Treatments
- Advanced Endocrine Therapy Approaches
Lung Cancer Studies
Conducts research in both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) treatments. Focuses on innovative therapeutic approaches including immunotherapy combinations and targeted treatments for specific molecular subtypes.
- Advanced NSCLC Treatment Strategies
- SCLC Therapeutic Innovations
- Targeted Molecular Therapies
Urological Oncology
Leads investigations in metastatic castration-resistant prostate cancer and advanced bladder cancer. Specializes in immunotherapy approaches and novel therapeutic combinations for urological malignancies.
- Prostate Cancer Treatment Innovations
- Bladder Cancer Immunotherapy
- Urothelial Carcinoma Management
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.